EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.2 — EX-99.2 FINANCIAL STATEMENTS
Exhibit 99.2
CONSOLIDATED FINANCIAL STATEMENTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
CONTENTS
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 1 |
|---|---|
| CONSOLIDATED BALANCE SHEETS | 2 |
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | 3 |
| CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY | 4 |
| CONSOLIDATED STATEMENTS OF CASH FLOWS | 6 |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS | 7-32 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.